5 recruiting, 2 active not recruiting, 1 terminated. 5 Phase 2, 2 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 4, Terminated 1 |
| Early Phase 1 | 2 | Active not recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Neuroendocrine Tumor Grade 2: new trials by email Literature Review of Neuroendocrine Tumor Grade 2 trials Research Report on Neuroendocrine Tumor Grade 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases Lutathera - Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2 | Phase 2 | Terminated | Imperial College London | 1 | 2024-08-02 | 2026-01-14 |
| Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial Somatostatin analog - Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1 | Phase 2 / Phase 3 | Recruiting | The Netherlands Cancer Institute | 39 | 2024-06-25 | 2025-03-03 |
| 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry Lutetium Lu 177 dotatate therapy - Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1 | Phase 2 | Recruiting | University of Iowa | 120 | 2024-05-03 | 2025-07-22 |
| Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors Everolimus 5 MG - Neuroendocrine Tumors, Progression | Phase 2 | Recruiting | AC Camargo Cancer Center | 100 | 2024-04-24 | 2024-06-25 |
| A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors [212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT - Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung | Early Phase 1 | Active not recruiting | David Bushnell | 24 | 2023-11-10 | 2025-11-04 |
| A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent [203Pb]VMT-α-NET, SPECT/CT - Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1 | Early Phase 1 | Active not recruiting | Yusuf Menda | 20 | 2022-08-22 | 2025-07-14 |
| CapTemY90 for Grade 2/3 NET Liver Metastases Capecitabine Oral Product, Temozolomide Oral Product, transarterial radioembolization - Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors | Phase 2 | Recruiting | Abramson Cancer Center at Penn Medicine | 70 | 2021-10-07 | 2026-10-08 |
| Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) Somatostatin analog; chemotherapy - Neuroendocrine Tumors, Neuroendocrine Neoplasm | Recruiting | University of Roma La Sapienza | 60 | 2020-09-14 | 2025-04-03 |
Neuroendocrine Tumors (7) · Adenoma, Islet Cell (2) · Carcinoid Tumor (1) · Carcinoma, Neuroendocrine (1) · Disease Progression (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Recurrence (1)
Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Germ Cell and Embryonal (7) · Neoplasms, Nerve Tissue (7) · Neuroectodermal Tumors (7) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Adenoma (2) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Disease Attributes (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Neoplasms by Site (2)
Somatostatin (2) · lutetium Lu 177 dotatate (2) · Capecitabine (1) · Drug Therapy (1) · Everolimus (1) · Single Photon Emission Computed Tomography Computed Tomography (1) · Temozolomide (1) · Yttrium-90 (1)
AC Camargo Cancer Center (1) · Abramson Cancer Center at Penn Medicine (1) · David Bushnell (1) · Imperial College London (1) · The Netherlands Cancer Institute (1) · University of Iowa (1) · University of Roma La Sapienza (1) · Yusuf Menda (1)
United States (4) · Brazil (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
Andrea Frilling, Prof (1) · Andrea M Isidori, MD, PhD (1) · David Bushnell, MD (1) · Michael Soulen (1) · Stephen Graves, Ph.D., DABR (1) · Yusuf Menda, M.D. (1)
R01CA243014 (2)